{
    "clinical_study": {
        "@rank": "83942", 
        "arm_group": {
            "arm_group_label": "SAR339658", 
            "arm_group_type": "Experimental", 
            "description": "Dose regimen every 2-4 weeks."
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To assess the long term safety and tolerability of SAR339658\n\n      Secondary Objective:\n\n      To assess the long term efficacy of SAR339658"
        }, 
        "brief_title": "Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "The total duration of study period is 68 weeks, broken down as follows:\n\n        -  1 week for screening (Week 8 assessment in the ACT12688 study)\n\n        -  62 weeks for treatment\n\n        -  6 weeks for the post treatment safety follow-up A post-study long term safety follow-up\n           will be performed in the form of a phone interview at 3, 6, 12, 18 and 24 months from\n           the last administration of the study medication."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with Ulcerative Colitis (UC) who were previously randomized and have\n             completed the 8-week treatment in ACT12688 study with an acceptable safety profile.\n             Patients who for administrative reasons could not be enrolled in the LTS12593 study\n             right after completion of the 8-week treatment in the ACT12688 study must be enrolled\n             within 3 months from the end of the ACT12688 study\n\n          -  Signed written informed consent for Study LTS12593\n\n        Exclusion criteria:\n\n          -  Patient with any adverse event leading to study drug (active or placebo) treatment\n             discontinuation from ACT12688 study.\n\n          -  Patient with any abnormalities or adverse events that per investigator judgment would\n             adversely affect patient's participation in the long-term extension study.\n\n          -  Use of any immunosuppressant (if patient is on immunosuppressant he or she must\n             discontinue immunosuppressant before starting the LTS12593).\n\n          -  If the patient started biological treatment for UC while waiting to be enrolled in\n             the LTS12593, then he or she must stop the biological treatment and must have 8 weeks\n             of wash out period before starting treatment with SAR339658 (only anti-TNFs are\n             allowed)\n\n          -  Patients exposed to an anti-integrin or any investigational drug administered after\n             the end of treatment in ACT12688\n\n          -  Positive pregnancy test\n\n          -  Breast feeding woman\n\n          -  Women of childbearing potential not protected by highly effective contraceptive\n             method of birth control and/or who are unwilling and unable to be tested for\n             pregnancy.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861249", 
            "org_study_id": "LTS12593", 
            "secondary_id": [
                "2013-001012-30", 
                "U1111-1141-4634"
            ]
        }, 
        "intervention": {
            "arm_group_label": "SAR339658", 
            "description": "Pharmaceutical form:Solution Route of administration: Intravenous", 
            "intervention_name": "SAR339658", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mission Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91345"
                    }, 
                    "name": "Investigational Site Number 840059"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miramar,", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33025"
                    }, 
                    "name": "Investigational Site Number 840008"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winter Park,", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32789"
                    }, 
                    "name": "Investigational Site Number 840048"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65265"
                    }, 
                    "name": "Investigational Site Number 840024"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Investigational Site Number 840088"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sugar Land", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77479"
                    }, 
                    "name": "Investigational Site Number 840038"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "Investigational Site Number 840068"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "zip": "V6Z 2K5"
                    }, 
                    "name": "Investigational Site Number 124002"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients who experience a Treatment Emergent Adverse Event (TEAE)", 
            "safety_issue": "Yes", 
            "time_frame": "At Week 62"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861249"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assessment of safety parameters (laboratory data and vital signs)", 
                "safety_issue": "Yes", 
                "time_frame": "At Week 62"
            }, 
            {
                "measure": "Percentage of patients who are in clinical remission", 
                "safety_issue": "Yes", 
                "time_frame": "At Week 62"
            }, 
            {
                "measure": "Proportion of patients with mucosal healing", 
                "safety_issue": "No", 
                "time_frame": "At Week 62"
            }, 
            {
                "measure": "Change from baseline in the partial Mayo Score", 
                "safety_issue": "No", 
                "time_frame": "At Weeks 10, 22, 34, 46 and 58"
            }, 
            {
                "measure": "Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)", 
                "safety_issue": "No", 
                "time_frame": "At Weeks 34 and 62"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}